Pfizer Inc
-
Open
34.08
-
Previous Close
34.06
-
Volume (Avg)
30.05M (21.72M)
-
Day's Range
33.97-34.22
-
52Wk Range
29.83-37.39
-
Market Cap.
203.92B
-
Dividend Rate (Yield)
1.28 (3.75%)
-
Beta
1.03
-
Shares Outstanding
5.97B
-
P/E Ratio (EPS)
28.74 (1.19)
Top Stories
-
UPDATE: Pfizer (PFE) gets CRL on Epoetin Alfa Biosimilar
StreetInsider 2 days agoPfizer Inc. (NYSE: PFE) today announced that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for its proposed epoetin alfa ...
-
Pfizer: Buy Shares On Price Weakness
Seeking Alpha -
Pfizer To Lose Exclusivity Of Key Brands
Seeking Alpha -
Traders take bullish position on Pfizer
NASDAQ -
Pfizer Downgraded To 3 Stars By Vetr Crowd
Benzinga 3 days agoThe Vetr community downgraded Pfizer Inc. (NYSE: PFE) from 3.5 stars to 3 stars. Pfizer shares have settled into a steady trading range over the past six months between $31 and $34, and the company's first-quarter earnings report in May showed a slight ...
-
Pfizer Becomes Oversold
NASDAQ -
The Baldwin Brothers Inc. MA Cuts Stake in Pfizer, Inc. (PFE)
healthcaremenu.net -
Pfizer Declares 32-Cent Third-Quarter 2017 Dividend
biospace.com -
Lilly, Pfizer get boost for non-opioid pain drug
Indianapolis Business Journal -
Being a Vaccine Heretic in the Church of Big Pharma
americaoutloud.com -
Pfizer Biosimilar Delayed By FDA Warning Letter
Law 360 -
Pfizer Wins Immediate Appeal Over Unsettled Whistleblower Questions
thelegalintelligencer.com -
Pfizer scientists devise 2-pronged attack against blood cancers
Fierce Biotech -
Pharmalittle: Pfizer biosimilar rejected again by FDA; families battle insurers over Sarepta drug
www.statnews.com -
STAT Plus: Pharmalittle: Pfizer biosimilar rejected again by FDA; families battle insurers over Sarepta drug
bioportfolio.com 1 day agoPfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ... Biosimilars or ...
-
US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning
in-Pharma -
Pfizer gets CRL on Epogen biosimilar from FDA
processandproduction.pharmaceutical-business-review.com -
Global Sulfasalazine Market 2017: Cadila, IPCA, Zydus, Pfizer and Icn Pharmaceuticals
Medgadget
